- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02594969
The Effect of Diluted Sodium Hypochlorite Solution and Moisturizers on Skin Barrier Function in Atopic Dermatitis (AD)
May 25, 2017 updated by: University of California, Davis
The goal is this study is to investigate the effects of dilute bleach on the skin of subjects with atopic dermatitis and those with healthy skin.
The second goal is to evaluate the effects of different moisturizers on the skin barrier of subjects with and without atopic dermatitis.
The investigators hypothesize that the bleach bath will increase the skin pH, decrease the skin hydration, and increase skin water loss in all study subjects.
Secondly, the investigators hypothesize that moisturizers with the lowest pH and the highest water to oil ratio will result in improved skin barrier function.
Furthermore, the investigators believe there will be a greater improvement in patients with atopic dermatitis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study has two main parts.
Subjects in both groups will have one forearm in a dilute bleach bath and the other arm in a water bath for 10 minutes.
The change in skin will be measured using different painless devices.
The second part of the study involves application of 4 various moisturizers.
The change in skin will be measured over a period of time using the non-invasive devices.
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Sacramento, California, United States, 95816
- UC Davis Department of Dermatology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 years to 65 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 8 years to 65 years
- Has been diagnosed with atopic dermatitis by a board-certified dermatologist at UC Davis
- Subject/parents/legal guardians able to read and comprehend the study procedure and consent forms.
Exclusion Criteria:
- Those who are pregnant, prisoners, or cognitively impaired
- Those who do not fit the inclusion criteria
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Healthy Group
These subjects do not have atopic dermatitis and are considered healthy.
They will participate in the bleach bath and the moisturizer application.
|
All subjects will have one forearm in a bleach bath and the other forearm in a water bath for 10 minutes.
Following the bath, skin barrier function will be evaluated.
Secondly, moisturizers will be applied to the arms and the skin barrier will be evaluated overtime.
Other Names:
|
|
Experimental: Atopic Dermatitis Group
These subjects have atopic dermatitis and are considered healthy.
They will participate in the bleach bath and the moisturizer application.
|
All subjects will have one forearm in a bleach bath and the other forearm in a water bath for 10 minutes.
Following the bath, skin barrier function will be evaluated.
Secondly, moisturizers will be applied to the arms and the skin barrier will be evaluated overtime.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in transepidermal water loss post-bath immersion
Time Frame: 10 minutes post-bath immersion
|
Subjects will immerse one randomized arm in a bleach bath and the other arm in a water bath for 10 minutes.
The skin barrier function will be evaluated for change in transepidermal water loss after 10 minutes of bath immersion.
|
10 minutes post-bath immersion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in transepidermal water loss after moisturizer application
Time Frame: up to 60 minutes post-moisturizer application
|
Each subject will have 4 various moisturizers placed on each arm.
The skin barrier function will be measured for change in transepidermal water loss to 60 minutes post-application..
|
up to 60 minutes post-moisturizer application
|
|
Change in skin hydration after moisturizer application
Time Frame: up to 60 minutes post-moisturizer application
|
Each subject will have 4 various moisturizers placed on each arm.
The skin barrier function will be measured for change in skin hydration up to 60 minutes post-application..
|
up to 60 minutes post-moisturizer application
|
|
Change in skin pH after moisturizer application
Time Frame: up to 60 minutes post-moisturizer application
|
Each subject will have 4 various moisturizers placed on each arm.
The skin barrier function will be measured for change in skin pH up to 60 minutes post-application..
|
up to 60 minutes post-moisturizer application
|
|
Change in skin hydration post-bath immersion
Time Frame: 10 minutes post-bath immersion
|
Subjects will immerse one randomized arm in a bleach bath and the other arm in a water bath for 10 minutes.
The skin barrier function will be evaluated for change in skin hydration after 10 minutes of bath immersion.
|
10 minutes post-bath immersion
|
|
Change in skin pH post-bath immersion
Time Frame: 10 minutes post-bath immersion
|
Subjects will immerse one randomized arm in a bleach bath and the other arm in a water bath for 10 minutes.
The skin barrier function will be evaluated for change in skin pH after 10 minutes of bath immersion.
|
10 minutes post-bath immersion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Eichenfield LF. Consensus guidelines in diagnosis and treatment of atopic dermatitis. Allergy. 2004 Aug;59 Suppl 78:86-92. doi: 10.1111/j.1398-9995.2004.00569.x.
- Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ, Schachner LA, Sidbury R, Whitmore SE, Sieck CK, Van Voorhees AS. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines". J Am Acad Dermatol. 2004 Mar;50(3):391-404. doi: 10.1016/j.jaad.2003.08.003. No abstract available. Erratum In: J Am Acad Dermatol. 2005 Jan;52(1):156.
- Rippke F, Schreiner V, Doering T, Maibach HI. Stratum corneum pH in atopic dermatitis: impact on skin barrier function and colonization with Staphylococcus Aureus. Am J Clin Dermatol. 2004;5(4):217-23. doi: 10.2165/00128071-200405040-00002.
- Ryan C, Shaw RE, Cockerell CJ, Hand S, Ghali FE. Novel sodium hypochlorite cleanser shows clinical response and excellent acceptability in the treatment of atopic dermatitis. Pediatr Dermatol. 2013 May-Jun;30(3):308-15. doi: 10.1111/pde.12150.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2014
Primary Completion (Actual)
May 1, 2015
Study Completion (Actual)
May 1, 2015
Study Registration Dates
First Submitted
July 10, 2014
First Submitted That Met QC Criteria
November 2, 2015
First Posted (Estimate)
November 3, 2015
Study Record Updates
Last Update Posted (Actual)
May 30, 2017
Last Update Submitted That Met QC Criteria
May 25, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 523979
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Caja Costarricense de Seguro SocialNot yet recruitingAtopic Dermatitis | Atopic Dermatitis (Eczema) | Atopic Dermatitis (AD) | Atopic Dermatitis / Eczema | Atopic Dermatitis, Unspecified | Atopic Dermatitis PatientsCosta Rica
-
Alphyn BiologicsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis (Eczema) | Atopic Dermatitis Eczema | Eczema, Atopic | Atopic Dermatitis (AD)Australia
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
En Chu Kong HospitalRecruitingSkin Diseases | Skin Diseases, Genetic | Skin Diseases, Eczematous | Atopic Dermatitis | Atopic Dermatitis (Eczema) | Atopic Dermatitis Eczema | Atopic Dermatitis (AD) | TCMTaiwan
-
Taipei Medical University Shuang Ho HospitalRecruitingAtopic Dermatitis (Eczema) | Atopic Dermatitis, ProbioticsTaiwan
-
Apollo Therapeutics LtdRecruitingDermatitis | Eczema | Dermatitis, Atopic | Atopic Dermatitis | Atopic | Eczema, Atopic | Dermatologic Disease | Eczema Atopic DermatitisUnited States, Spain, Germany, Canada, Bulgaria, Poland, Czechia, Hungary
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
PfizerTerminatedEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
Corvus Pharmaceuticals, Inc.RecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Eczema, AtopicUnited States
-
Evommune, Inc.CompletedEczema | Atopic Dermatitis (AD) | Eczema Atopic DermatitisNew Zealand, Australia
Clinical Trials on Bleach Bath and Moisturizers
-
University of North Carolina, Chapel HillCompletedEczema | Atopic Dermatitis | Atopic Dermatitis and Related ConditionsUnited States
-
Baylor College of MedicineCompletedCommunity-Acquired Staphylococcus AureusUnited States
-
University of RochesterNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompleted
-
Duke UniversityCompletedHealthcare Associated Infections | Multidrug Resistant OrganismsUnited States
-
Washington University School of MedicineCompletedStaphylococcal Skin Infection | Abscess | Furunculosis | Staphylococcus Aureus | MRSA InfectionUnited States
-
University of ArizonaTerminatedCoccidioidomycosis | Valley FeverUnited States
-
Riphah International UniversityCompleted
-
Acibadem UniversityCompletedPain, Postoperative | Sleep Deprivation | Nursing CariesTurkey
-
St. Jude Children's Research HospitalAvadim Technologies, Inc.CompletedTheraworx Bath Wipes Versus Standard Bath Wipes in the Reduction of Vancomycin-Resistant EnterococciHematopoietic Stem Cell Transplantation | Vancomycin-Resistant EnterococciUnited States